Medtronic changes investor relations leadership ahead of diabetes spinout

Core Insights - Medtronic is planning to spin out its diabetes unit, MiniMed, into a standalone company by the end of 2026, with an initial public offering as the preferred method for separation [3][9] - The company has appointed Ryan Weispfenning to lead the investor relations function at MiniMed, leveraging his 17 years of experience in Medtronic's investor relations team [4][5][9] - Ingrid Goldberg has been hired as the new vice president and head of investor relations at Medtronic, previously holding a similar role at Novocure [6][9] Group 1 - Medtronic's separation of its diabetes unit is on track for completion by the end of 2026 [3] - The company aims for MiniMed to become an independent, publicly traded entity [5] - Weispfenning's strong relationships with analysts and investors are expected to be beneficial for MiniMed's transition [5] Group 2 - Goldberg's background includes significant experience in medtech investor relations, having worked at Abiomed and Bluebird Bio [7][9] - The leadership change in investor relations is part of Medtronic's strategy to prepare for the spin-off of its diabetes division [9]